Review Article
Dendritic Cell-Based Immunotherapy for Prostate Cancer
Table 1
PCa-associated antigen-derived CD8+ T-cell epitopes used for DC-based immunotherapy.
| Antigen | HLA restriction element | Peptide position | Amino acid sequence | References |
| Prostate-specific antigen (PSA) | HLA-A2 | 146–154 | KLQCVDLHV | [23, 24] | 141–150 | FLTPKKLQCV | [25, 26] | 154–163 | VISNDVCAQV | [25–27] | Prostate-specific membrane antigen (PSMA) | HLA-A2 | 4–12 | LLHETDSAV | [28, 29] | 711–719 | ALFDIESKV | [29] | Prostatic acid phosphatase (PAP) | HLA-A2 | 299–307 | ALDVYNGLL | [30] | Prostate stem cell antigen (PSCA) | HLA-A2 | 14–22 | ALQPGTALL | [31, 32] | Prostein | HLA-A2 | 31–39 | CLAAGITYV | [33] | Transient receptor potential-p8 (Trp-p8) | HLA-A2 | 187–195 | GLMKYIGEV | [34] | Human telomerase reverse transcriptase (hTERT) | HLA-A2 | 540–548 | ILAKFLHWL | [35, 36] | Survivin | HLA-A2 | 95–104 | ELTLGEFLKL | [37, 38] |
|
|